Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Esophageal Cancer.

Although kinase inhibitors have improved outcomes for many cancer patients ... site while being more selective for FGFR3 (versus FGFR1, FGFR2, and FGFR4) to minimize off-target toxicities.

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

Examination of 81 cancerous colon tumors showed a high percentage of fatty acids linked to ultra-processed foods. Ganesh Halade, associate professor in the USF Health Heart Institute in the ...

A tumor marker for pancreatic cancer helps healthcare professionals detect, diagnose, or treat it. However, a person can have high tumor marker levels without having cancer. Tumor markers are ...

KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers Malignant phyllodes tumors (MPTs) are rare fibroepithelial tumors of the breast with aggressive ...

Prevalence and Distribution of Unexpected Actionable Germline Pathogenic Variants Identified on Broad-Based Multigene Panel Testing Among Patients With Cancer The National Cancer Institute-Molecular ...

High-fructose corn syrup, a sweetener made from corn starch, is widely found in common foods. Due to its widespread use, the consumption of fructose has increased over the past five decades.